InvestorsHub Logo
Followers 11
Posts 1565
Boards Moderated 0
Alias Born 09/19/2006

Re: None

Thursday, 08/10/2017 9:14:50 AM

Thursday, August 10, 2017 9:14:50 AM

Post# of 6377
The company is on track to announce results of the 19 patient phase II partial trial by year end. No specific numbers but doing well in enrollment.

CML trial to start in weeks at MD Anderson by Dr. Cortez.

IND for 3rd drug candidate needs additional protections to proceed.

Prexigebersen has being tested (animal?) for solid tumor reduction and the particle size (nano) which is necessary for the drug success has now happened.

New patent now allows for DNAbilize licensing.

Shorting and removal from Russell was blamed for low stock price.

No information on the company's efforts to address NASDAQ delisting. No information on when a CFO will be hired.

They would not allow me to ask questions.

It was not worth getting up early to listen to this disappointing conference.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News